The DASH SARS-CoV-2/S Test provides results in approximately 15 minutes and runs on the DASH Analyser. Credit: Business Wire / Minute Molecular Diagnostics.

Minute Molecular Diagnostics has received emergency use authorisation (EUA) from the US Food and Drug Administration (FDA) for its DASH SARS-CoV-2/S Test.

The new reverse transcription-quantitative polymerase chain reaction (RT-qPCR) assay is designed for the rapid qualitative detection of RNA from SARS-CoV-2 using an anterior nasal swab.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

It provides results in approximately 15 minutes and runs on the DASH Analyser, which consolidates the sample extraction and PCR.

The point-of-care technology was developed at the Center for Innovation in Global Health Technologies (CIGHT) of Northwestern University, Illinois. It is being commercialised by Minute Molecular Diagnostics.

The National Institutes of Health (NIH) provided $21.3m to the company for the manufacturing of the new DASH SARS-CoV-2/S Test.

Minute Molecular co-founder and chief scientific officer Dr Sally McFall said: “DASH enables non-laboratory personnel to insert a nasal swab specimen directly into our test cartridge and then load the cartridge into the DASH instrument, providing an accurate result in about 15 minutes.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“The simplicity of the DASH test adds an important, new tool for schools, universities, congregate care settings and workplaces.”

The company stated that the test is limited to use in Clinical Laboratory Improvement Amendments of 1988 (CLIA) certified laboratories.

The DASH Covid-19 Rapid PCR test has received authorisation for use at the point of care (POC), for example in patient care settings that operate under a CLIA Certificate of Waiver, Certificate of Compliance or Certificate of Accreditation.

Minute Molecular is starting its Covid-19 diagnostic test production as well as seeking both government and private partnerships to expedite test and analyser delivery.